Amanda Doyle, MD
Dermatology · Brooklyn, NYNPI 1497049548
Payments from drug & device makers
Across 714 payments — averaging $334.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$205K
- AbbVie$25K
- Galderma Laboratories, L.p.$1K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$1K
- Incyte Corporation$648
- Sanofi$590
- plus $5K from 29 others
Across 3 payments — averaging $6055.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz North America, Inc.$18K
What the payments were for
- Consulting fees$65,08262%
- Speaking & faculty fees$3500%
- Travel & lodging$23,53922%
- Food & beverage$16,21015%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 112 | $205,410 |
| AbbVie(2 entities) | 112 | $24,710 |
| Galderma Laboratories, L.p. | 70 | $1,125 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 90 | $1,084 |
| Incyte Corporation | 44 | $648 |
| Sanofi | 28 | $590 |
| Pfizer | 29 | $571 |
| Almirall LLC | 28 | $526 |
| LEO Pharma Inc. | 27 | $517 |
| Amgen | 18 | $452 |
| Biofrontera Inc. | 4 | $441 |
| Regeneron Healthcare Solutions, Inc. | 34 | $369 |
| Sun Pharmaceutical Industries Inc. | 19 | $337 |
| Mayne Pharma Commercial LLC | 22 | $318 |
| VYNE Pharmaceuticals Inc. | 15 | $306 |
| Bristol Myers Squibb | 14 | $194 |
| Dermira, Inc. | 6 | $166 |
| Journey Medical Corporation | 3 | $115 |
| Dermavant Sciences, Inc. | 2 | $112 |
| EPI Health, LLC | 5 | $101 |
| DUSA Pharmaceuticals, Inc. | 4 | $86 |
| Lilly USA, LLC | 3 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Organon | 4 | $70 |
| Glenmark Therapeutics Inc. | 4 | $58 |
| Arcutis Biotherapeutics, Inc. | 2 | $44 |
| Taro Pharmaceuticals USA, Inc. | 2 | $33 |
| Medimetriks Pharmaceuticals, Inc. | 2 | $32 |
| Botanix SB Inc | 2 | $32 |
| Abbott | 1 | $27 |
| Novartis | 1 | $25 |
| Aclaris Therapeutics, Inc. | 1 | $25 |
| Encore Dermatology Inc. | 1 | $22 |
| Mylan Pharmaceuticals Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$238,725 in reported general payments places this provider in the 90th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 17 | $212 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Brooklyn
- Hilary BaldwinBrooklyn$2.1M
- Jeannette JakusBrooklyn$1M
- Steven BaranowitzBrooklyn$625K
- Nanette SilverbergBrooklyn$489K
- Susan BardBrooklyn$425K
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.